Brain Cancer

Metastatic Breast Cancer

Breast Cancer

Colorectal Cancer

Gastric Cancers

Liver Cancer

Gastrointestinal Cancer

Bladder Cancer

Kidney Cancer

Prostate Cancer

Genitourinary Cancer

Cervical Cancer

Endometrial Cancer

Ovarian Cancer

Gynecologic Cancers

Head and Neck Cancers

Graft-Vs-Host Disease

Leukemia

Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Hematology

Lung Cancer

Pediatric Cancer

Sarcomas

Melanoma

Skin Cancer

Adding E-602 to cemiplimab demonstrated anti-tumor effects in patients PD-L1–resistant solid cancers. 

Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers

Mitazalimab combined with mFOLFIRINOX led to responses and survival benefits in patients with metastatic pancreatic ductal adenocarcinoma. 

Mitazalimab Plus mFOLFIRINOX Improves Survival in Pancreatic Cancer

The novel drug SHR-A1921 was safe and efficacious in patients with platinum-resistant ovarian cancer, according to phase 1 data. 

Novel ADC Shows Promise in Platinum-Resistant Ovarian Cancer

Docetaxel was associated with lower rates of peripheral neuropathy compared with paclitaxel for Black patients with breast cancer. 

Chemo Should be Tailored to Decrease Neuropathy in Black Patients

News

Latest News

FDA News

Adverse Event Management

Supportive Care

Disparities in Cancer Care

Drug Safety

Radiation Oncology

Survivorship 

Practice Management

Prevention

Contributors

Media

Expert Connections

Morning Rounds

The Vitals

Podcasts

Videos

Between the Lines

Conferences

Conference Coverage

Conference Listing

Publications

CME/CE

Continuing Education

Resources

Case-Based Digest 

Rx Road Map

Webinars

Cancer Summary Slides

MPN Symptom Management

Events

Subscribe

Partners

Oncology nurses “play a pivotal role in guiding patients” through the genetic testing process, an expert explained. 

Nurses Can Help ‘Demystify’ Genetic Testing Results

Articles

Most patients with triple-negative breast cancer experienced a protocol-defined immune response with an investigational vaccine, phase 1 data showed. 

Cancer Vaccine Sparks Immune Response in TNBC

The FDA received a biologics license application for accelerated approval of RP1 plus nivolumab for advanced, pretreated melanoma. 

Accelerated Approval Sought for RP1-Nivolumab Combo for Pretreated Melanoma

PARP inhibitors have changed the way we think about [managing] ovarian cancer,” Whitney Goldsberry, MD, said 

Consider BRCA, HRD Status Before Deciding on a PARP Inhibitor for Ovarian Cancer

CancerNetwork.com

CureToday.com

OncLive.com

TargetedOnc.com

Advertise

Privacy

Terms & Conditions

Do Not Sell My Information

Oncology Nursing News

Facebook

LinkedIn

Specialty

Advanced Practice Providers

Clinical

Gynecologic Cancer

Immunotherapy

Nurse Navigation

Quality Improvement

1rem

Preliminary findings from the SLI phase of the BEACON CRC trial show tri-drug combo has durable response in patients with BRAF V600E-mutant metastatic CRC.

Triplet Regimen Shows Durable Responses in BRAF V600E-Mutant Metastatic CRC

, Holly Chitwood, DNP, FNP-C, AGACNP-BC, walks through a patient case with a 70-year-old male with metastatic colorectal cancer.

 His providers used circulating tumor DNA (ctDNA) testing to monitor his minimal residual disease (MRD) levels throughout active treatment. This approach, although not currently addressed in National Comprehensive Cancer Center Guidelines, allows patients and providers to have an idea of how the treatment is working earlier compared with what imaging can usually demonstrate, she explains.

Chitwood is an assistant professor in the College of Nursing at the University of Kentucky, as well as a practicing oncology APRN who primarily cares for patients with gastrointestinal, hepatic-biliary, and sarcoma tumors in her clinic. To read the full case study, please check out our show notes below.

“This is a new technology that we have. It is basically looking at what is in your blood to see how much circulating tumor DNA is floating around.”

“In this case, and in a lot of my patients, you will see ctDNA is about, you know, anywhere from 2 to 3 months [ahead], predating what you will see on imaging.”

“You have to be very judicious in explaining the results, 

 if you have a positive result, and the patient should be included in the decision making.”

ctDNA Continues to Emerge As A Potentially Useful Disease Monitoring Tool in CRC

ctDNA Makes Headway as Promising Marker for Patients With Anal Cancer and Other GI Malignancies

ESMO Guideline on Liquid Biopsy Address Quality Standards for Clinical Implementation

New Treatment Methods Launch a Shift in CRC Treatment

Terri Pollack Offers Perspective on 2023 ASCO GI Cancers Symposium

Chitwood H, Myers A. Use of circulating tumor DNA to monitor minimal residual disease among patients with colorectal cancer. 

 2023;27(4):369-374. doi:10.1188/23.CJON.369-374

Holly Chitwood, DNP, FNP-C, AGACNP-BC, explains how circulating tumor DNA monitoring helps providers screen minimal residual disease in individuals with colorectal cancer. 

ctDNA Monitoring is a Piece of the Puzzle in CRC Treatment

Higher corticosteroid peak dose may worse progression-free and overall survival in several tumor types including melanoma, non-small cell lung cancer, and others. 

Higher Corticosteroid Peak Dose May Worsen Survival in Patients With Treatment-Related Adverse Events

Olanzapine improved control of nausea and vomiting from moderately emetogenic chemotherapy, which may suggest its use as a standard of care for antiemetic prophylaxis. 

Olanzapine May Prevent Nausea and Vomiting During Moderately Emetogenic Chemotherapy

The FDA approved the Shield blood test for colorectal screening in adults aged 45 years and older with an average risk for the disease.

FDA Approves Shield Blood Test to Screen for CRC in Adults

Nivolumab plus ipilimumab improved health-related quality of life and reduced symptom burden in patients with microsatellite instability–high/mismatch repair–deficient mCRC.

Nivolumab Plus Ipilimumab May Ease Symptom Burden in MSI-H/dMMR Metastatic Colorectal Cancer

Disease-free survival and overall survival improved with celecoxib plus advanced chemotherapy in patients with PIK3CA-mutated stage III colon cancer.

Colorectal Cancer

Latest News

More News

Latest Conference Coverage